

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**偉俊 生 物 科 技 有 限 公 司**

**Wai Chun Bio-Technology Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 660)**

## **PROFIT WARNING**

This announcement is made by Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on preliminary assessment of the unaudited consolidated management accounts of the Group and the information currently available, the Group is expected to record a loss attributable to the owners of the Company ranging from approximately HK\$19,000,000 to HK\$25,000,000 for the eighteen months ended 30 June 2022 as compared with the loss attributable to the owners of the Company of approximately HK\$8,149,000 for the year ended 31 December 2020. The expected increase in the loss attributable to the owners of the Company for the eighteen months ended 30 June 2022 was mainly due to, among other things, the combined effect of (i) an increase in interest expenses on convertible bonds by not less than approximately HK\$13,000,000 for the eighteen months ended 30 June 2022 because the convertible bonds were issued in November 2020 and January 2022 as compared with interest expenses on convertible bonds of approximately HK\$729,000 for the year ended 31 December 2020; (ii) the recognition of loss on issuance of convertible bonds for the eighteen months ended 30 June 2022 while there were no such loss recognised for the year ended 31 December 2020; and (iii) the recognition of loss on alteration of the terms of convertible bonds for the eighteen months ended 30 June 2022 while there were no such loss recognised for the year ended 31 December 2020.

The interest expenses mentioned above in (i) are mainly made of non-cash interest expenses, and the losses mentioned above in (ii) and (iii) are non-cash flows items, and those expenses and losses do not give any material effect to the business operation of the Group.

The Company is still in the process of finalising the consolidated results of the Group for the eighteen months ended 30 June 2022. The information contained in this announcement can only be treated as a preliminary assessment by the Board based on the latest unaudited consolidated management accounts of the Group, which is subject to adjustments or amendments (if any), and the information currently available, and is not based on any figures nor information that has been audited, confirmed and/or reviewed by the auditor of the Company. Shareholders and potential investors of the Company are advised to read the annual results announcement of the Company for the eighteen months ended 30 June 2022 which is expected to be published on 14 November 2022.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Wai Chun Bio-Technology Limited**  
**Chan Cheuk Ho**  
*Executive Director*

Hong Kong, 8 November 2022

*As at the date of this announcement, the Board consists of one executive Director, namely Mr. Chan Cheuk Ho and two independent non-executive Directors, namely Mr. Wan Bo and Ms. Hong Ting.*